(:NLTX)

Dec 14, 2023 07:00 pm ET
Neoleukin Therapeutics Announces 1-for-4 Reverse Stock Split
Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors...
Sep 22, 2023 08:00 am ET
Neoleukin Therapeutics Announces 1-for-5 Reverse Stock Split
Neoleukin Therapeutics, Inc., “Neoleukin” or the “Company” (NASDAQ:NLTX), a biopharmaceutical company that has designed de novo protein therapeutics utilizing sophisticated computational methods, today announced that its Board of Directors...
Aug 21, 2023 05:36 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – NLTX, DEN, BG, SCU
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 17, 2023 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NLTX, SCU, AMNB
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Neoleukin Therapeutics, Inc. (NASDAQ:...
Aug 16, 2023 01:32 pm ET
SHAREHOLDER ALERT: Morris Kandinov Investigating HAFC, CVNA, PEGA, and NLTX; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Hanmi Financial Corporation, Carvana Co., Pegasystems Inc., and Neoleukin Therapeutics, Inc. If you are a current owner of shares of any of...
Aug 14, 2023 06:00 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, DEN, NLTX, BG
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Aug 09, 2023 08:57 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NEX, AEL, NLTX, RETA
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: NexTier Oilfield Solutions Inc....
Aug 09, 2023 06:21 pm ET
SHAREHOLDER ALERT: Morris Kandinov Investigating CVNA, DNA, NLTX, and PEGA; Shareholders are Encouraged to Contact the Firm
National law firm Morris Kandinov is investigating the actions of the officers and board of directors of Carvana Co., Ginkgo Bioworks Holdings, Inc., Neoleukin Therapeutics, Inc. and Pegasystems Inc.   If you are a current owner of shares of any of...
Aug 07, 2023 05:00 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, TALS, NLTX, CCF
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and...
Aug 01, 2023 03:37 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTX
NEW YORK, Aug. 1, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 31, 2023 05:31 pm ET
STOCKHOLDER ALERT: The M&A Class Action Firm Continues Investigating the Merger – AJX, NLTX, SCU, CCF
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 26, 2023 10:17 am ET
Moore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law Firm
Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.   Moore Kuehn may seek...
Jul 25, 2023 10:49 am ET
NEOLEUKIN THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Neoleukin Therapeutics, Inc. - NLTX
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Neoleukin Therapeutics, Inc. (NasdaqCM: NLTX) with Neurogene Inc. Under the terms of the proposed transaction, pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company (subject to certain adjustments) and will also be issued contingent value rights to receive certain payments from proceeds received by the combined company, if any, related to Neoleukin’s pre-transaction legacy assets or from savings rea
Jul 25, 2023 12:00 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCU, PRDS, NLTX, AJX
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc....
Jul 24, 2023 07:30 pm ET
ALERT: The M&A Class Action Firm Continues Investigating the Merger – SCU, NLTX, HCCI, CCF
Juan Monteverde, founder and managing partner of the class action firm Monteverde & Associates PC (the “M&A Class Action Firm”), a national securities firm rated Top 50 in the 2018-2021 ISS Securities Class Action Services Report and headquartered...
Jul 24, 2023 12:58 pm ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCU, PRDS, NLTX, AJX
NEW YORK, July 24, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 24, 2023 09:35 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Sculptor Capital Management Inc. (NYSE – SCU), Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience,
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jul 22, 2023 08:07 pm ET
Lifshitz Law PLLC Announces Investigations of HCCI, PRDS, NLTX, CCF
Heritage-Crystal Clean, Inc. (NASDAQ: HCCI) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the sale of HCCI to an investment affiliate of J.F. Lehman & Company for $45.50 per share in...
Jul 19, 2023 05:35 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PRDS, NLTX, KLR
Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Pardes Biosciences, Inc. (NASDAQ:...
Jul 18, 2023 12:16 pm ET
Shareholder Alert: Ademi LLP investigates whether Neoleukin Therapeutics, Inc. has obtained a Fair Price in its Private Placement and its transaction with Neurogene
MILWAUKEE, July 18, 2023 /PRNewswire/ -- Ademi LLP is investigating Neoleukin (Nasdaq: NLTX) for possible breaches of fiduciary duty and other violations of law in its private placement and its transaction with Neurogene. 
Jul 18, 2023 10:39 am ET
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQ
NEW YORK, July 18, 2023 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Jul 18, 2023 10:20 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Neoleukin Therapeutics, Inc. (Nasdaq - NLTX), Pardes Bioscience, Inc. (Nasdaq – PRDS), Kaleyra, Inc. (NYSE – KL
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Jul 18, 2023 07:16 am ET
NLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Neoleukin Therapeutics, Inc. (NASDAQ: NLTX) and Neurogene Inc. is fair to Neoleukin shareholders. Pre-merger Neoleukin stockholders are expected to own approximately 16% of the combined company.
Jul 18, 2023 06:30 am ET
Neurogene and Neoleukin Announce Definitive Merger Agreement
Neurogene Inc., a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, and Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) today announced that they have entered into a...
Mar 08, 2023 05:00 pm ET
Neoleukin Therapeutics Provides Strategic Update and Announces Restructuring and Leadership Transition
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it has engaged SVB Securities to assist in reviewing...
Dec 12, 2022 01:00 pm ET
Neoleukin Therapeutics Presents Preclinical Data on NEO-TRA1 at American Society of Hematology (ASH) Annual Meeting
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today presented data on NEO-TRA1, a precision-tuned agonist of the IL-2...
Nov 14, 2022 04:03 pm ET
Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results and Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the third quarter ended September 30,...
Nov 03, 2022 09:05 am ET
Neoleukin Therapeutics Announces Oral Presentation at 64th American Society of Hematology (ASH) Annual Meeting
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced an oral presentation at the upcoming American Society of...
Aug 09, 2022 04:02 pm ET
Neoleukin Therapeutics Announces Second Quarter 2022 Financial Results & Provides Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2022...
Aug 03, 2022 08:00 am ET
Neoleukin Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Jul 27, 2022 08:00 am ET
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
Neoleukin Therapeutics, Inc., "Neoleukin” (NASDAQ:NLTX), today announced it will report second quarter 2022 financial results on Tuesday, August 9, 2022 after the close of financial markets and then host a conference call and live audio webcast to...
May 16, 2022 08:00 am ET
Neoleukin Therapeutics Announces First Patient Treated in Combination Arm of Phase 1 Trial Evaluating NL-201 in Combination with KEYTRUDA® (pembrolizumab)
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced treatment of the first patient in a combination arm...
May 09, 2022 04:05 pm ET
Neoleukin Therapeutics Announces First Quarter 2022 Financial Results and Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2022 and...
May 05, 2022 08:00 am ET
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Apr 13, 2022 10:00 am ET
Neoleukin Therapeutics Announces Preclinical Data for NL-201 at American Association for Cancer Research (AACR) Annual Meeting
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data and a trial in progress...
Apr 07, 2022 08:00 am ET
Neoleukin Therapeutics to Present at Canaccord Genuity Horizons in Oncology Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Mar 15, 2022 08:00 am ET
Neoleukin Therapeutics Announces Appointment of Donna Cochener as General Counsel
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Donna M. Cochener as General Counsel,...
Mar 08, 2022 04:01 pm ET
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Annual Meeting
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three presentations at the upcoming American Association for...
Mar 01, 2022 04:03 pm ET
Neoleukin Therapeutics Announces Year End 2021 Financial Results and Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the year ended...
Feb 22, 2022 08:00 am ET
Neoleukin Therapeutics to Host 2021 Financial Results Conference Call and Webcast on March 1, 2022
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced , today announced it will report full year 2021 financial...
Feb 03, 2022 08:00 am ET
Neoleukin Therapeutics to Present at Guggenheim Healthcare Talks 2022 Oncology Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Jan 10, 2022 08:00 am ET
Neoleukin Therapeutics Announces Clinical Collaboration with Merck to Evaluate NL-201 in Combination with KEYTRUDA® (pembrolizumab)
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a clinical trial collaboration and supply agreement with...
Jan 10, 2022 06:00 am ET
Neoleukin Therapeutics Presenting at H.C. Wainwright BIOCONNECT Virtual Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Dec 11, 2021 05:30 pm ET
Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology Annual Meeting (ASH 2021)
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on NL-201 in multiple...
Nov 12, 2021 07:05 am ET
Neoleukin Therapeutics Presents NL-201 Preclinical Data at Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of new preclinical data on NL-201, an...
Nov 09, 2021 08:00 am ET
Neoleukin Therapeutics to Present at Upcoming Investor Conferences
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in two upcoming investor...
Nov 04, 2021 04:05 pm ET
Neoleukin Therapeutics Announces Third Quarter 2021 Financial Results and Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third...
Oct 01, 2021 09:07 am ET
Neoleukin Therapeutics Announces Multiple Abstracts Accepted for Presentation at the Society for Immunotherapy of Cancer’s 36th Annual Meeting (SITC 2021)
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of four abstracts to be presented at the...
Sep 29, 2021 08:00 am ET
Neoleukin Therapeutics Announces Oral Presentation at IDWeek 2021 of Data Demonstrating that NL-CVX1, a Computationally Designed De Novo Protein, Can Block Infection by SARS-CoV-2 Viral Variants of Co
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced new data highlighting the ability of its de novo protein...
Sep 09, 2021 08:00 am ET
Neoleukin Therapeutics Announces Appointment of Bill Arthur, Ph.D., as Vice President and Head of Research
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Bill Arthur, Ph.D., as Vice President and...
Sep 07, 2021 08:00 am ET
Neoleukin Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Aug 05, 2021 04:05 pm ET
Neoleukin Therapeutics Announces Second Quarter 2021 Financial Results & Provides Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ended June 30, 2021...
Aug 04, 2021 08:00 am ET
Neoleukin Therapeutics to Participate in Canaccord Genuity 41st Annual Growth Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
May 26, 2021 08:00 am ET
Neoleukin Therapeutics to Participate in Jefferies Virtual Healthcare Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
May 12, 2021 08:00 am ET
Neoleukin Therapeutics Announces First Quarter 2021 Financial Results and Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the quarter ending March 31, 2021 and...
May 05, 2021 08:00 am ET
Neoleukin Therapeutics Announces Initiation of Phase 1 NL-201 Trial
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced dosing the first patient in a Phase 1 trial of NL-201 for...
May 04, 2021 08:00 am ET
Neoleukin Therapeutics to Participate in BofA Securities 2021 Healthcare Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
May 03, 2021 08:00 am ET
Neoleukin Therapeutics Announces Appointment of Priti Patel, M.D., M.S., as Chief Medical Officer
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Priti Patel, M.D., M.S., as Chief Medical...
Apr 26, 2021 07:00 am ET
Neoleukin Therapeutics Announces Clearance to Proceed with NL-201 Phase 1 Clinical Trial in the United States
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has removed...
Mar 25, 2021 04:00 pm ET
Neoleukin Therapeutics Announces Year End 2020 Financial Results
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the year ended...
Mar 18, 2021 08:00 am ET
Neoleukin Therapeutics to Host 2020 Financial Results Conference Call and Webcast on March 25, 2021
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2020 financial results on Thursday,...
Mar 02, 2021 08:00 am ET
Neoleukin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Feb 05, 2021 08:00 am ET
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks 2021 Oncology Days
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Jan 08, 2021 08:00 am ET
Neoleukin Therapeutics Receives Clinical Hold Letter from U.S. FDA Related to CMC Assay Development for NL-201
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that on January 7, 2021, it received a clinical hold letter...
Jan 07, 2021 08:00 am ET
Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Dec 10, 2020 08:00 am ET
Neoleukin Therapeutics Announces Submission of Investigational New Drug Application for NL-201 De Novo Protein Immunotherapy Candidate for Cancer
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the submission of an Investigational New Drug (IND)...
Nov 23, 2020 08:00 am ET
Neoleukin Therapeutics Announces Participation in Piper Sandler 32nd Annual Virtual Healthcare Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Nov 11, 2020 08:00 am ET
Neoleukin Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Nov 10, 2020 08:00 am ET
Neoleukin Therapeutics Presents Preclinical Combination Data for NL-201 at Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on its lead...
Nov 09, 2020 08:00 am ET
Neoleukin Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results and a corporate update for the third...
Nov 05, 2020 02:00 pm ET
Neoleukin Therapeutics Announces Publication in Science of De Novo Protein Decoys that Block COVID-19 Infection In Vitro and Protect Animals In Vivo
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the publication in Science of research describing novel...
Oct 20, 2020 08:00 am ET
Neoleukin Therapeutics Appoints Holly K. Vance as General Counsel
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Holly K. Vance as General Counsel. Ms....
Oct 14, 2020 05:05 pm ET
Neoleukin Therapeutics Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC 2020)
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the acceptance of a preclinical data abstract on its lead...
Sep 10, 2020 08:00 am ET
Neoleukin Therapeutics Announces Appointment of Martin Babler to Board of Directors
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Martin Babler, President and Chief...
Sep 09, 2020 08:00 am ET
Neoleukin Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Aug 12, 2020 04:01 pm ET
Neoleukin Therapeutics Announces Second Quarter 2020 Financial Results & Provides Corporate Update
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the second quarter ending June 30, 2020...
Aug 06, 2020 08:00 am ET
Neoleukin Therapeutics to Present at Canaccord Genuity 40th Annual Growth Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that management will participate in a fireside chat at the...
Aug 05, 2020 08:00 am ET
Neoleukin Therapeutics to Host Second Quarter 2020 Financial Results & Corporate Update Conference Call and Webcast on August 12, 2020
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report second quarter 2020 financial results on...
Jul 02, 2020 09:00 am ET
Neoleukin Therapeutics Announces Pricing of $76.2 Million Public Offering
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 3,262,471...
Jul 01, 2020 04:01 pm ET
Neoleukin Therapeutics Announces Proposed Public Offering
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and...
Jun 22, 2020 09:05 am ET
Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the presentation of preclinical data on its lead...
Jun 15, 2020 08:00 am ET
Neoleukin Therapeutics to Host Investor R&D Showcase Highlighting De Novo Protein Therapeutics
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will host a virtual Investor R&D Showcase on Tuesday, June...
Jun 01, 2020 08:00 am ET
Neoleukin Therapeutics Announces Appointment of Erin Lavelle to Board of Directors
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Erin Lavelle to the company’s Board of...
May 27, 2020 08:00 am ET
Neoleukin Therapeutics to Present at Jefferies Virtual Healthcare Conference
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
May 15, 2020 07:00 am ET
Neoleukin Therapeutics Announces Multiple Presentations at American Association for Cancer Research (AACR) Virtual Annual Meeting II
Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced three presentations at the American Association for Cancer...
May 07, 2020 08:00 am ET
Neoleukin Therapeutics to Present at Virtual BofA Securities 2020 Health Care Conference
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
May 06, 2020 04:01 pm ET
Neoleukin Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update
Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced financial results for the first quarter ending March 31,...
Apr 16, 2020 04:05 pm ET
Neoleukin Therapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held May 5, 2020
Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, announced today that, due to the public health impact of the coronavirus...
Apr 09, 2020 08:00 am ET
Neoleukin Therapeutics Provides Update on COVID-19 Impact on Corporate and Clinical Development Activities
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today provided an update on the impacts of COVID-19 on the company’s corporate...
Mar 12, 2020 04:01 pm ET
Neoleukin Therapeutics Announces Year End Financial Results
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the year ending...
Mar 05, 2020 08:00 am ET
Neoleukin Therapeutics to Host 2019 Financial Results Conference Call and Webcast on March 12, 2020
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it will report full year 2019 financial results on Thursday,...
Feb 25, 2020 08:00 am ET
Neoleukin Therapeutics Announces Appointment of Robert K. Ho as Chief Financial Officer
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointment of Robert Ho as Chief Financial Officer,...
Feb 24, 2020 08:00 am ET
Neoleukin Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Feb 06, 2020 08:00 am ET
Neoleukin Therapeutics to Participate in Guggenheim Healthcare Talks Idea Forum | Oncology Day
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Dec 20, 2019 04:01 pm ET
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the closing of its public offering of 10,263,750 shares of...
Dec 17, 2019 10:26 pm ET
Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 8,925,000...
Dec 17, 2019 04:38 pm ET
Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and...
Dec 05, 2019 08:00 am ET
Neoleukin Therapeutics Announces Scientific Advisory Board
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the formation of a Scientific Advisory Board comprised of...
Nov 26, 2019 08:00 am ET
Neoleukin Therapeutics to Present at Piper Jaffray 31st Annual Healthcare Conference
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will...
Nov 13, 2019 09:15 am ET
Neoleukin Therapeutics Announces Corporate Update and Third Quarter 2019 Financial Results
Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced a corporate update and financial results for the third quarter...
Sep 19, 2019 08:00 am ET
Neoleukin Therapeutics Announces Additions to Management Team
Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the appointments of Leslie Aberman as Vice President, Legal...
Sep 05, 2019 04:05 pm ET
Neoleukin Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neoleukin Therapeutics, Inc. (“Neoleukin”) (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced it has granted equity awards that were approved by the...
Aug 06, 2019 07:00 am ET
Aquinox Pharmaceuticals and Neoleukin Therapeutics announce merger agreement
Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP) and Neoleukin Therapeutics, Inc. (“Neoleukin”), a privately held biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.